Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Kiyatec to Sponsor and Exhibit at the Virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022


Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced the company is sponsoring and exhibiting at the virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022. Details regarding this event can be found here: https://www.abta.org/national-conference-2022/

The ABTA National Conference is the only advocacy-led educational meeting designed specifically for patients, survivors and caregivers that brings together the entire brain tumor community. Held annually, thousands of attendees learn from the nation's leading experts about the latest advances in brain tumor research, treatment and care.

Leveraging its innovative 3D cell culture technology platform for both clinical and pre-clinical use, Kiyatec recently introduced its first commercial assay in the US, 3D Predicttm Glioma. The Company is accelerating its commercial and business development services while securing payer pricing, coverage and reimbursement. The Kiyatec assay for ovarian cancer continues its evidence generation in ovarian cancer. Kiyatec is finalizing its facilities expansion in support of the Company's five-year growth plan with increased laboratory capacity and accelerating its ex vivo 3D cell culture assay development in rare, breast and lung cancers.

About Kiyatec

Kiyatec is the first functional precision oncology company with published, clinically correlated evidence measuring the predictive therapeutic response of patient live cancer cells using its innovative 3D cell culture technology platform. The Company offers clinical tests for high-grade glioma and is developing tests for ovarian, breast, non-small cell lung and rare tumors in its CLIA-certified lab. The Company works with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. For more information, visit www.kiyatec.com and connect with us on LinkedIn and Twitter.


These press releases may also interest you

at 09:00
Guidewire announced that Guidewire PartnerConnect Consulting and Global Premier partner, Ernst & Young LLP (EY), has achieved the global Migration Acceleration Specialization. Partners who have earned this specialization have demonstrated the...

at 09:00
The Commerce Casino & Hotel, home to the largest poker room in the world, proudly announces an exciting partnership with the richest, most prestigious, and longest-running poker series ? the World Series of Poker® (WSOP®). This collaboration...

at 09:00
The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp , a global leader of innovative diagnostic and biopharma laboratory services, to serve as its...

at 09:00
Rex 3 recently opened its doors to students from Florida Atlantic University (FAU) for Rex 3's 11th Annual 101 Printing Tour, reinforcing its commitment to community engagement and education in the printing industry. This tour provided students with...

at 09:00
GigaMedia Limited today announced its unaudited financial results for the fourth quarter and full year of 2023. Highlights For 2023, GigaMedia reported revenues of $4.3 million, with a gross profit of $2.4 million, an operating loss of $3.2 million...

at 09:00
Yardi® is proud to sponsor the 2024 Manufactured Housing Institute (MHI) Congress & Expo, April 3-4, at the iconic MGM Grand in Las Vegas. At the exhibit hall attendees can explore the newest product innovations, accessible April 3, from 1 p.m. to...



News published on and distributed by: